Last $0.05 USD
Change Today 0.00 / 0.00%
Volume 0.0
VNAPF On Other Exchanges
Symbol
Exchange
London
OTC US
As of 4:30 PM 04/25/14 All times are local (Market data is delayed by at least 15 minutes).

verona pharma plc (VNAPF) Key Developments

Verona Pharma plc, Annual General Meeting, Jun 12, 2014

Verona Pharma plc, Annual General Meeting, Jun 12, 2014., at 10:00 GMT Standard Time. Location: at the offices of SGH Martineau LLP, 5th Floor. Agenda: To receive and adopt the report of the directors and the financial statements for the year ended 31 December 2013 and the report of the auditors thereon; to approve the directors' remuneration report for the year ended 31 December 2013; to consider reelection of directors; to re-appoint UHY Hacker Young LLP as auditors; to allot and make offers to allot relevant securities; and to consider the allotment of equity securities.

Verona Pharma plc Presents at BioEquity Europe 2014, May-22-2014 02:00 PM

Verona Pharma plc Presents at BioEquity Europe 2014, May-22-2014 02:00 PM. Venue: Hilton Amsterdam Hotel, Amsterdam, Netherlands.

Verona Pharma plc Reports Audited Group and Company Earnings Results for the Year Ended December 31, 2013

Verona Pharma plc reported audited group and company earnings results for the year ended December 31, 2013. For the period, the company reported operating loss of GBP 2,816,784 compared to GBP 2,585,349 a year ago. Loss before taxation was GBP 2,814,152 compared to GBP 2,565,172 a year ago. Loss for the year was GBP 2,524,752 compared to GBP 2,517,103 a year ago. Basic and diluted loss per ordinary share was 0.74 pence compared to 0.82 pence a year ago. Net cash outflow from operating activities was GBP 2,343,944 compared to GBP 2,573,609 a year ago. Purchase of plant and equipment was GBP 2,033 compared to GBP 46,594 a year ago. For the period, on a company basis, the company reported net cash outflow from operating activities of GBP 2,332,329 compared to GBP 2,561,282 a year ago. Purchase of plant and equipment was GBP 2,033 compared to GBP 46,594 a year ago. Operating loss was GBP 2,814,267 compared to GBP 2,582,534 a year ago.

Verona Pharma plc to Report Fiscal Year 2013 Results on Apr 28, 2014

Verona Pharma plc announced that they will report fiscal year 2013 results on Apr 28, 2014

Verona Pharma plc Presents at 2013 Therapeutic Area Partnerships Conference, Nov-19-2013 10:40 AM

Verona Pharma plc Presents at 2013 Therapeutic Area Partnerships Conference, Nov-19-2013 10:40 AM. Venue: One Avenue De Lafayette, Boston, MA 02111, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VNAPF:US $0.05 USD 0.00

VNAPF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VNAPF.
View Industry Companies
 

Industry Analysis

VNAPF

Industry Average

Valuation VNAPF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERONA PHARMA PLC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.